- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02750137
Ametop - Friend and Foe A Prospective Study of the Incidence of Adverse Reactions With Ametop
Ametop - Friend or Foe A Prospective Observational Study of the Incidence of Adverse Reactions With Ametop
Studieoversigt
Detaljeret beskrivelse
Ametop was introduced into the formulary as it was deemed more efficacious for intravenous cannulation compared to EMLA. After several critical incidences of adverse reactions that occurred with its application, a departmental audit was carried out to look at the incidence and severity reactions with its application as well as its outcome on intravenous cannulation. The findings of the departmental audit showed that the incidence of adverse reactions seemed to occur more commonly compared to other studies.
A prospective observational study was carried out to look at the incidence and severity of skin reactions following routine clinical application of Ametop.
This study aims to achieve the following:
- Investigate the incidence and severity of adverse skin reactions following topical application of Ametop prior to intravenous cannulation
- Assess the success rate of intravenous cannulation
- Identify the possible risk factors associated with adverse skin reaction.
Undersøgelsestype
Tilmelding (Faktiske)
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- All paediatric patients presenting for surgery from August 2014 to May 2015 who have had Ametop applied prior to intravenous cannulation.
Exclusion Criteria:
- Any patient who did not have Ametop applied or have an intravenous cannula in situ.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of skin reactions with Ametop
Tidsramme: October 2014 to May 2015
|
looking at the incidence of skin reactions with Ametop - normal, simple erythema, raised erythema, itch, pallor
|
October 2014 to May 2015
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Risk factors associated with incidence of skin reactions
Tidsramme: October 2014 to May 2015
|
Looking at possible factors associated with skin reactions - race, duration of application, history of atopy
|
October 2014 to May 2015
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Angela YJ Tan, MMed, KK Women's and Children's Hospital
Publikationer og nyttige links
Generelle publikationer
- Browne J, Awad I, Plant R, McAdoo J, Shorten G. Topical amethocaine (Ametop) is superior to EMLA for intravenous cannulation. Eutectic mixture of local anesthetics. Can J Anaesth. 1999 Nov;46(11):1014-8. doi: 10.1007/BF03013194.
- Arrowsmith J, Campbell C. A comparison of local anaesthetics for venepuncture. Arch Dis Child. 2000 Apr;82(4):309-10. doi: 10.1136/adc.82.4.309.
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2015/2158
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .